39.63

7.49% -3.21

Neurogene Inc (NGNE)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$42.84

Offen:

$42.74

24-Stunden-Volumen:

290.57K

Relative Volume:

1.44

Marktkapitalisierung:

$790.63M

Einnahmen:

$925.00K

Nettoeinkommen (Verlust:

$-98.64M

KGV:

-7.8958

EPS:

-5.0191

Netto-Cashflow:

$-83.37M

1W Leistung:

+12.14%

1M Leistung:

+41.49%

6M Leistung:

+121.15%

1J Leistung:

+80.46%

1-Tages-Spanne:

$38.18

$43.00

1-Wochen-Bereich:

$32.00

$43.66

52-Wochen-Spanne:

$15.93

$43.66

Neurogene Inc Stock (NGNE) Company Profile

Firmenname

Neurogene Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

(877) 237-5020

Adresse

535 W 24TH STREET, NEW YORK

Mitarbeiter

131

Twitter

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NGNE Neurogene Inc	39.63	790.63M	925.00K	-98.64M	-83.37M	-5.0191
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-17	Eingeleitet	Craig Hallum	Buy
2025-05-16	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-06-11	Eingeleitet	Robert W. Baird	Outperform
2024-04-29	Eingeleitet	Leerink Partners	Outperform
2024-03-21	Eingeleitet	William Blair	Outperform
2024-01-08	Eingeleitet	H.C. Wainwright	Buy
2024-01-05	Eingeleitet	Stifel	Buy
2024-01-04	Eingeleitet	TD Cowen	Outperform

Alle ansehen

Neurogene Inc Aktie (NGNE) Neueste Nachrichten

Jul 09, 2026

Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews

Jul 09, 2026

Jul 08, 2026

Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News

Jul 08, 2026

Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan

Jul 07, 2026

Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Canada

Jul 07, 2026

A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo

Jul 07, 2026

Jul 06, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 06, 2026

Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan

Jul 06, 2026

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Jul 06, 2026

Jul 04, 2026

Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView

Jul 04, 2026

Jul 03, 2026

Neurogene prices $125M equity offering - MSN

Jul 03, 2026

Neurogene announces pricing of $125 million public offering - The Pharma Letter

Jul 03, 2026

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com

Jul 02, 2026

Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan

Jul 02, 2026

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha

Jul 02, 2026

Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView

Jul 02, 2026

Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com

Jul 02, 2026

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa

Jul 01, 2026

Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria

Jul 01, 2026

Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share - Investing.com

Jul 01, 2026

Neurogene Sets Pricing For $125 Million Public Offering - TradingView

Jul 01, 2026

Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada

Jul 01, 2026

Neurogene Prices $125 Million Public Offering - marketscreener.com

Jul 01, 2026

Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan

Jul 01, 2026